Cancer statistics, 2020

Bibliographic Data

ID23322949
AuthorsRebecca L Siegel (0000-0001-5247-8522, Surveillance and Health Services Research American Cancer Society Atlanta Georgia, corresponding author), Kimberly D Miller (0000-0002-2609-2260, Surveillance and Health Services Research American Cancer Society Atlanta Georgia), Ahmedin Jemal (0000-0002-0000-4111, Surveillance and Health Services Research American Cancer Society Atlanta Georgia)
Year2020
Volume70
Issue1
Pages7-30
Publication date2020-01-01
Peer ReviewedYes
Open AccessYes
TypeARTICLE
VenueCA: A Cancer Journal for Clinicians (JOURNAL)
Journal identifiersISSN: 0007-9235 • E-ISSN: 1542-4863
PublisherWiley (PUBLISHER • GB)
DOI10.3322/caac.21590
PMID31912902
OpenAlexW2999417355
LanguageEN
Citations received97
References cited59

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population‐based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statistics. In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States. The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted. This progress is driven by long‐term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008‐2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer. In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single‐year drop in overall cancer mortality of 2.2% from 2016 to 2017. Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined. Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013. It is also notable that long‐term rapid increases in liver cancer mortality have attenuated in women and stabilized in men. In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.

Breast cancer · Cancer · Colorectal cancer · Environmental health · Epidemiology of cancer · Health statistics · Incidence (geometry) · Lung cancer · Mortality rate · Population · Prostate cancer · Cancer Genomics and Diagnostics · Demography · Economic and Financial Impacts of Cancer · Epidemiology · Global Cancer Incidence and Screening · Internal Medicine · Medicine · Oncology · Gerontology

Tools

Open DOISci-HubOpen Access